Roche reports positive Phase II results for experimental eye drug

New Drug Approvals

Lampalizumab

Roche reports positive Phase II results for experimental eye drug
Lampalizumab, an experimental eye drug from Roche, has helped slow down the progression of an advanced form of age-related macular degeneration (AMD) in a Phase II study, the company announced this week.

READ ALL AT

 http://www.pharmaceutical-technology.com/news/newsroche-reports-positive-phase-ii-results-experimental-eye-drug?WT.mc_id=DN_News

SEE ALSO

Lampalizumab effective in Phase II clinical trial for macular degeneration

Roche’s new drug for age-related macular degeneration, lampalizumab, showed effective in slowing the progression of AMD in patients with advanced disease, shrinking the area of geographic atrophy by 20%. Read More >>

 

Lampalizumab (INN) is a humanized monoclonal antibody designed for the treatment of geographic atrophy secondary to age-related macular degeneration. It binds to CFD.^[1][2]

This drug was developed by Genentech/Roche.

References

1. ^World Health Organization (2012). “International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107” (PDF). WHO Drug…

View original post 21 more words